New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
07:39 EDTAUXL, AGN, ENDP, ACTAuxilium would be "ideal" takeover target, says Stifel
Stifel sees Auxilium as an "ideal" target, due to its men’s health/urology platform. The firm thinks that the most likely suitors would be Allergan (AGN), Endo Health (ENDP), and Actavis (ACT). It believes that Allergan would be the best match, and predicts that Auxilium could be bought for a 15%-30% premium. The firm stipulates that it does not know of any M&A talks involving Auxilium. It keeps a Buy rating on Auxlium.
News For AUXL;AGN;ENDP;ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
September 22, 2014
06:09 EDTAUXLStocks with implied volatility below IV index mean; AUXL YELP
Subscribe for More Information
05:52 EDTACTActavis downgraded to Equal Weight from Overweight at Barclays
Subscribe for More Information
September 19, 2014
16:24 EDTAUXL, ENDPStocks rise after Fed keeps pledge for 'considerable time' before rate hike
Subscribe for More Information
14:18 EDTACTAkorn competition settlement over VersaPharm deal approved by FTC
Subscribe for More Information
11:25 EDTAGNSenators bring bill requiring companies to settle before inverting
U.S. Senators Sherrod Brown and Dick Durbin announced new legislation requiring corporations to "Pay What You Owe Before You Go" – settling their U.S. tax bill before relocating to a foreign country. "Everyone knows that before you leave a restaurant you have to settle your tab," Brown said. "Corporations shouldn’t get to play by different rules. While it is critical that we reach a long-term solution that reforms our international corporate tax code by implementing a global minimum tax and reducing the statutory tax rate, this bill is an immediate, commonsense measure to ensure businesses settle up before leaving the U.S." Among the deals or possible transactions that involve inversion are Mylan's (MYL) acquisition of Abbott (ABT), Medtronic's (MDT) acquisition of Covidien (COV) and Valeant's (VRX) proposed takeover of Allergan (AGN).
10:28 EDTAUXLOptions with decreasing implied volatility
Subscribe for More Information
10:06 EDTAUXLOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:22 EDTAUXLAuxilium downgraded to Neutral from Buy at UBS
Subscribe for More Information
September 18, 2014
20:23 EDTAUXL, ENDPAuxilium downgraded to Neutral from Buy at Goldman
Goldman Sachs downgraded Auxilium (AUXL) to Neutral citing a balanced risk/reward following the post-Endo (ENDP) takeover bid rally. The firm raised its price target for shares to $31 from $28.
16:27 EDTAUXLOn The Fly: Closing Wrap
Subscribe for More Information
16:20 EDTAUXLBioSpecifics says data suggests support for potential label expansion of XIAFLEX
Subscribe for More Information
12:45 EDTAUXLOn The Fly: Midday Wrap
Subscribe for More Information
11:15 EDTENDP, AUXLRepros sinks after panel backs tests for testosterone therapies
Subscribe for More Information
10:00 EDTAUXLOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:59 EDTAUXLOn The Fly: Pre-market Movers
Subscribe for More Information
07:50 EDTENDP, AUXLEndo Auxilium deal would be disappointing over longer term, says Cantor
Subscribe for More Information
07:24 EDTAUXLAmerican Society for Surgery of the Hand to hold annual meeting
69th Annual Meeting of ASSH to be held in Boston on September 18-20.
07:02 EDTAUXLAuxilium presents XIAFLEX data from MULTICORD Phase 3b study
Subscribe for More Information
06:10 EDTENDP, AUXLFDA panel votes 20-1 to study changes to testosterone therapies
Subscribe for More Information
06:05 EDTAUXLVIVUS, Auxilium announce FDA approval of STENDRA sNDA
VIVUS (VVUS) and Auxilium Pharmaceuticals (AUXL) announced that the FDA has approved a supplemental new drug application, or sNDA, for STENDRA. STENDRA is now the only FDA-approved erectile dysfunction, or ED, medication indicated to be taken as early as approximately 15 minutes before sexual activity. STENDRA is a prescription medication in a class of drugs known as phosphodiesterase type 5, or PDE5, inhibitors approved for the treatment of ED in men 18 years or older. STENDRA is available in multiple dosage strengths and may be taken with or without food and moderate alcohol consumption. In clinical studies, when compared to placebo, STENDRA helped more men achieve an erection in as early as approximately 15 minutes that lasted long enough to successfully complete sexual intercourse.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use